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A CONTROLLED, PROSPECTIVE LONGITUDINAL, INTERVENTIONAL, 
NATURALISTIC STUDY TO EVALUATE THE UNIQUE HEALTH CARE 
PROGRAM “CONVERSATION MAP©” FOR TURKISH PATIENTS WITH 
TYPE-2 DIABETES IN ONE GERMAN MAJOR CITY
Korolewa V, Kretschmer B, Clouth J
Lilly Deutschland GmbH, Bad Homburg, Germany
OBJECTIVES: Considering a cultural and epidemiological disparity between Turkish 
and German type-2 diabetes patients in Germany, resulting in a health care gap, a 
customised diabetes program for Turkish migrants is required. The objective was to 
evaluate “Conversation Map©”, a unique health care education program for Turkish 
migrants with type-2 diabetes in Germany. METHODS: Ninety-two Turkish patients 
with poor German language skills were divided into interventional (IV, n = 44) and 
control (C, n = 48) groups, 42 German (G) patients served as additional control group. 
The IV group attended a structured once weekly, 2 hr “Conversation Map©” training 
over 4 weeks in Turkish language. The two control groups had no intervention. 
Sociodemographic data were recorded at baseline, and standardized questionnaires 
assessing treatment, diabetes-knowledge (0–6; 6 = everything right), and therapy 
adherence (“Essential Training Content (ETC)” 0–10; 10 = best) were applied at 
baseline and after 4 weeks after training in the IV group. Baseline differences between 
the groups and changes of data after 4 weeks compared to baseline were tested (paired 
t-test, α = 0.05, two-sided). RESULTS: Ethnic groups were comparable on demo-
graphic data, whereas Turkish patients had lower education level (P < 0.001). 55% 
of all Turkish patients (IV and C) were insulin-dependent and 63% were previously 
not attending any diabetes-training. Baseline diabetes knowledge of Turkish patients 
was signiﬁ cantly lower than in the German control group (IV 2.38, T 2.77, G: 4.10, 
P < 0.001), as well as the ETC score (IV 6.37, C 5.92, G 7.98, P < 0.001). After 
“Conversation Map©” training the Turkish group achieved signiﬁ cantly higher mean 
knowledge- and ETC-score values compared to baseline (difference +70%, ETC: 
+25%, P < 0.001) and were comparable to the German group. CONCLUSIONS: The 
study demonstrated that the cultural sensitive training “Conversation Map©”, led to 
a signiﬁ cant increase of disease-knowledge and therapy adherence, helping to improve 
the health care situation of Turkish patients, with cost savings potential in the long 
term.
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TIME TO ADD-ON MEDICATION USE FOR PATIENTS WITH TYPE 2 
DIABETES MELLITUS (T2DM) WHO FAILED METFORMIN 
MONOTHERAPY
Qiu Y1, Fu AZ2, Radican L1
1Merck & Co., Inc., Whitehouse Station, NJ, USA; 2Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Add-on medications are recommended if target glycemic goals for 
patients with T2DM are not achieved or sustained after initial metformin mono-
therapy. This study examined the time to add-on medication use after metformin 
monotherapy failure in clinical practice. METHODS: Selected from a large US EMR 
database between Janujary 1, 1997 and December 31, 2008, included patients had to 
be aged ≥18 years with a diagnosis of T2DM who had HbA1c ≥ 7.0% or ≥ two fasting 
blood glucose levels of 126 mg/dL or greater. Treatment failure was deﬁ ned as HbA1c 
≥ 7% (index date) after metformin monotherapy for at least 6 months. Baseline data 
were extracted during 1 year prior to the index date. Time to add-on medication use 
was time between index date to the ﬁ rst add-on medication use during follow-up and 
was evaluated for the overall cohort and for three index HbA1c subgroups: <8%, 
8–9%, and >9%. a Cox proportional hazard model was employed to determine 
baseline clinical and demographic characteristics associated with shorter time to 
add-on medication use. RESULTS: There were 12,566 patients meeting the inclusion 
criteria; 8656, 2175 and 1735 had index HbA1c < 8%, 8–9% and >9%, respectively. 
The overall mean (SD) age was 63 (12) years and 51% were female. The median time 
to add-on medication use was 15.7 months overall and 17.0, 13.9 and 11.3 months 
for patients with index HbA1c < 8%, 8–9% and >9%, respectively. Higher index A1c, 
greater body mass index, higher Charlson comorbidity index, younger age, males, 
lower LDL were signiﬁ cantly associated with shorter time to add-on medication use 
(all P < 0.05). CONCLUSIONS: This indicates, in US clinical practice, it takes over 
a year for a diabetic patient who has suboptimal glycemic level after initial metformin 
monotherapy to receive add-on medications. There is room through disease manage-
ment so that patients who have failed metformin monotherapy, if eligible and appro-
priate, receive add on therapy sooner rather than later.
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PRESCRIBED DAILY DOSES OF ONCE-DAILY LIRAGLUTIDE IN THE 
GERMAN STATUTORY HEALTH INSURANCE (SHI)
Schöffski O1, Mentrup S2, Lund N3
1Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany; 2Novo Nordisk 
Pharma GmbH, Mainz, Germany; 3Novo Nordisk A/S, Soeborg, Denmark
OBJECTIVES: To evaluate the prescribed daily dose of liraglutide for patients in 
German statutory health insurances. The novel once-daily incretin analogue, liraglu-
tide, mimics the effect of endogenous glucagon-like peptide 1 (GLP-1). Liraglutide was 
launched in Germany in July 2009 in a device allowing 3 different dosages (0.6 mg 
for initial titration; and the two maintenance doses 1.2 and 1.8 mg). The deﬁ ned daily 
dose (DDD) was set by WHO at 1.2 mg. The prescribed daily dose (PDD) has not 
been evaluated so far. METHODS: Sampled data from German statutory health 
insurances (SHI) was provided by Insight Health (patient tracking data) for the period 
from July 2009 to March 2010 (9 months) covering about 11% of all patients in 
German SHI. All patients with prescriptions of liraglutide were identiﬁ ed (n = 4,284). 
Patients with only one prescription and less than 4 weeks between ﬁ rst and last date 
of prescription were excluded to avoid overrepresented inﬂ uence of low dosed therapy 
starters (remaining patients: n = 2,118). Total number of prescribed pens was deter-
mined from ﬁ rst to second last prescription and total consumption in mg was calcu-
lated. Number of days between ﬁ rst and last prescription was determined and mean 
average consumption in mg per day was calculated. RESULTS: The mean PDD of 
liraglutide in 2118 patients was 1.28 mg. Sensitivity analyses including only patients 
with longer periods of use showed decreasing average consumption; patients with at 
least 10 weeks duration of treatment showed a mean daily dose of 1.25 mg. Stocking 
effects (prescription before package is empty) could have driven the increase in average 
use in the starting period and at the end of the calendar year. CONCLUSIONS: The 
longer patients use liraglutide the lower the observed PDDs. The DDD of 1.2 mg is a 
valid estimate for real life usage of liraglutide.
PDB83
TIME TO TREATMENT MODIFICATION AMONG PATIENTS WITH TYPE 
2 DIABETES WHO INITIATED EXENATIDE OR INSULIN GLARGINE
Pawaskar M1, Bonafede M2, Johnson BH3, Fowler R3, Hoogwerf B4
1Eli Lilly & Company, Indianapolis, IN, USA; 2Thomson Reuters, Cambridge, MA, USA; 
3Thomson Reuters, Washington, DC, USA; 4Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: To examine time to treatment modiﬁ cation for patients with type 2 
diabetes (T2D) initiating treatment with exenatide BID or insulin glargine. METHODS: 
A retrospective analysis was conducted using the Thomson Reuters Research Data-
bases. Adult patients with T2D who initiated exenatide (N = 9197) or glargine (N = 
4499) between October 1, 2006 and September 30, 2007 with 12 months pre- and 
18 months post-index continuous enrollment were included. Treatment modiﬁ cation 
was deﬁ ned as the ﬁ rst event of change in the treatment and was classiﬁ ed further into 
three types: intensiﬁ cation, switching or discontinuation of the index medication. The 
2 cohorts were 1:1 propensity score matched on baseline demographics, clinical 
characteristics, and prior health care utilization. Survival analysis was used to examine 
time to treatment modiﬁ cation. RESULTS: Propensity score matching resulted in 
inclusion of 3774 exenatide and 3774 glargine patients with a mean age of 57 years, 
mean Deyo Charlson Comorbidity Index score of 1.6, and with proportionately more 
males (54%) than females. All of the patients concomitantly used a non-index antidia-
betes medication in post-index period. The 18-month discontinuation rates were 
38.3% and 40.0% (P = 0.14) and the treatment intensiﬁ cation rates were 15.9% and 
26% (P < 0.0001) for exenatide and glargine, respectively. Alternatively, 14.9% of 
exenatide-treated patients switched therapies, compared to 10.0% of glargine-treated 
patients (P < 0.0001). Glargine-treated patients were 33% more likely to modify 
treatment than exenatide-treated patients (Hazard Ratio (HR): 1.33, P < 0.0001). 
Glargine-treated patients were 72% more likely to intensify their treatment (HR = 
1.72, P < 0.0001), 25% more likely to discontinue (HR = 1.25, P < 0.0001), and 29% 
less likely to switch to new therapy (HR = 0.71, P < 0.0001) compared to exenatide. 
CONCLUSIONS: This analysis showed that exenatide-treated patients were less likely 
to modify their treatment suggesting potential longer durability with exenatide 
therapy. Furthermore, exenatide-treated patients were less likely to discontinue or 
intensify but more likely to switch their treatment than glargine-treated patients.
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MANAGEMENT OF ACROMEGALY IN CLINICAL PRACTICE 
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Roset M1, Merino-Montero S1, Luque M2, López-Mondéjar P3, Salinas I4, Soto A5, 
Bernal C6, Villabona C7, De Luis D8, Donnay S9, Pascual H10, Pérez-Luis J11
1IMS Health, Barcelona, Spain; 2Hospital Universitario La Princesa Servicio de Endocrinología 
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Barcelona, Spain; 8Sección de Endocrinología y Nutrición Clínica, Unidad de Apoyo a la 
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OBJECTIVES: The goal of treating acromegaly is directed at removing the tumor, 
preventing tumor re-growth and reducing long-term morbidity and mortality. For this 
purpose, different health resources are necessary. This study evaluates the disease 
resources and costs in Spain. METHODS: An epidemiological, prospective, natural-
istic, multicentric study (30 endocrinologists) involving acromegalic patients with 
micro (≤10 mm) or macro (>10 mm) adenomas was performed. Patients were catego-
rised as Surgical Group (SG) (surgery in the 6 months before inclusion or during 
follow-up period and somatostatin analogue (SA) treatment for <6 months during the 
pre-surgery period) and Medical Treatment Group (MTG) (patients receiving SA 
treatment for ≥6 months, with/without surgery following SA treatment). Resource data 
were collected from standard visits during a 2-years period. RESULTS: The study 
included 74 patients (56 SG and 18 MTG). Most patients were women (62%). The 
mean (SD) age was 49 (14) years. The annual direct acromegaly cost per patient is 
c9668 (c9223 SG vs. c11,054 MTG). The cost of illness was higher in patients with 
macroadenoma than in microadenoma (c11,053 vs. c5809), and it is increased in 
young patients (<40 years). Surgical procedures in acromegaly (involving hospitaliza-
tion and complementary tests) constitute the 22% and 8% of the illness cost in SG 
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and MTG patients. Additionally, hospitalizations in intensive care units (50% SG vs. 
22% MTG patients), emergency visits (21% SG vs. 6% MTG) and the presence of 
adenoma complications (73% SG vs. 44% MTG) constitute a source of cost increment 
in these patients. Patients who accomplish with the most strict study clinical control 
criteria (GH < 1.0 and IGF-1 < 100%) showed the lowest direct cost of illness (c6169 
vs. c12,990). CONCLUSIONS: The economic cost of acromegaly is dependent on the 
clinical control of the disease. Direct cost of illness is the half that the cost in non 
controlled patients.
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APPROVAL AFTER REJECTION—AN INSIGHT IN HTA RE-EVALUATIONS
Sweeney N, Andreykiv M, Wiebinga C
Quintiles Consulting, Hoofddorp, The Netherlands
OBJECTIVES: To gain insight into the re-evaluation process of HTA agencies after 
an initial rejection and identify the adaptations that led to the approval of re-submitted 
dossiers. METHODS: Phase I: manual search of 57 health care agencies’ websites for 
published diabetes-related assessments (January 2007-May 2010). Phase II: the two 
most re-assessed drugs for which detailed information was available were selected for 
further evaluation (insulin glargine and exenatide). For these drugs, all reports pub-
lished prior to 2007 were also included. RESULTS: Phase I identiﬁ ed 117 relevant 
single technology appraisals; 18 were re-evaluations. Six agencies performed re-eval-
uations of the same drug after an initial rejection: CADTH, CVZ, HAS, PBAC, 
AHTAPol and SMC. To date, SMC evaluated 32 submissions for 13 anti-diabetic 
drugs, PBAC published 20 (eight drugs), CADTH 13 (four drugs), CVZ 14 (four 
drugs) and AHTAPol 10 (two drugs). In phase II insulin glargine (four re-submissions 
to PBAC and 1 to CADTH) and exenatide (two re-submissions to PBAC, 1 to CVZ 
and 1 to AHTAPol) were evaluated. It became clear that payers do focus on overall 
cost. The approach that was chosen for those two drugs was to control overall cost 
either by restricting access or by settling on a lower price. CVZ accepted exenatide 
for reimbursement only after restricting access to a subgroup of obese type 2 diabetes 
mellitus patients (with an ICER of c5.231). Instead of patient segmentation PBAC 
insisted on lowering the price for both medications (rationale for insulin glargine being 
concern that prescribing cannot be contained within the deﬁ ned population). 
AHTAPol limited exenatide reimbursement to 50% to control prescribing rates. 
CONCLUSIONS: For the diabetes cases analyzed HTA agencies attempted to control 
health care expenditure by either lowering drug costs or by narrowing the deﬁ nition 
of the target population, the latter inevitably allowing fewer patients access to the 
drug.
PDB86
HEALTH TECHNOLOGY ASSESSMENT OF DIABETES COMPOUNDS: 
THE POLISH PERSPECTIVE
Adalsteinsson JE1, Czech M2, Skrekowska-Baran I3, Jasik BM1
1Novo Nordisk A/S, Copenhagen, Denmark; 2Department of Pharmacoeconomics, Medical 
University of Warsaw, Warsaw, Poland; 3Novo Nordisk Pharma Sp, Warszawa, Poland
OBJECTIVES: The AOTM in Poland was established to give MoH in Poland advice 
on reimbursement. The aim of this research is to create an overview of HTA reports 
on diabetes compounds in Poland and the results of the decision making. METHODS: 
A search was conducted on the webpage of AOTM (http://www.aotm.gov.pl) for HTA 
reports on the following products: Rosiglitazon, Pioglitazon, Sitagliptin, Vildagliptin, 
Saxagliptin, Exenatide, Liraglutide, Glargine, Detemir, Aspart, Glulisene and Lispro. 
RESULTS: Of a total of 163 reports (published between 2007 and 2010), eight reports 
in Polish language on diabetes were identiﬁ ed and assessed. Two reports can be viewed 
as secondary assessment of regulatory safety discussions. The other six reports assessed 
the implementation of new diabetes compounds with assessment of efﬁ cacy, safety 
and cost-effectiveness of the drugs.Two reports assessed safety concerns associated 
with the risk of cancer and concluded based on EMA and FDA research that no 
increased risk was associated with these agents. Rosiglitazone and Sitagliptin were not 
recommended for reimbursement due to availability of other treatments with similar 
efﬁ cacy. Saxagliptin, Exenatide and Liraglutide got the recommendation to be reim-
bursed due to expected increase in QALYs. The ﬁ nal report was assessing Glulisene 
which got the recommendation to temporary reimburse (2 years) provided that data 
on hard endpoints (not speciﬁ ed in public report) and cost-effectiveness should be 
delivered. CONCLUSIONS: Recommendation by AOTM is supported by assessment 
of available RCTs, cost per life-year gained, cost per QALY, estimated budget impact 
for 5 years and also in some cases reports from EMEA, FDA and other HTA agencies 
(SMC, PBAC and CADTH). The AOTM’s recommendation is not obligatory for the 
Polish Ministry of Health.
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STANDARDS FOR THE ASSESSMENT OF ANTIDIABETIC DRUGS—THE 
IQWIG PERSPECTIVE
Schweikert B1, John J2, Ringborg A3, Erhardt W4, Bleckmann A5, Neubauer AS4
1i3 Innovus, Aschheim, Germany; 2Helmholtz Zentrum München, Neuherberg, Germany; 3i3 
Innovus, Stockholm, Sweden; 4Bristol-Myers Squibb, München, Germany; 5AstraZeneca, 
Wedel, Germany
OBJECTIVES: A substantial number of new pharmaceutical treatment strategies have 
been introduced for the treatment of diabetes mellitus type II. The availability of these 
drugs for patients in different countries depends on the evaluation standards and 
methods applied in the various phases of drug assessment. Objective of this research 
was to review the requirements and criteria applied for the assessment of antidiabetic 
drugs along the regulatory process by EMA (Europe) and FDA (USA) for the assess-
ment of efﬁ cacy and safety as well as for reimbursement decisions by NICE (England) 
and IQWiG (Germany) and to compare their consistency, with a special focus on 
IQWiG’s procedures. METHODS: A review of relevant current method documents 
and reports on evaluations of antidiabetic drugs published by IQWiG was conducted. 
These were compared with guidance documents issued by FDA, EMA and NICE with 
respect to endpoints considered in diabetes and their deﬁ nition, criteria for the type 
of evidence, and potential comparators. RESULTS: Consistently, across all agencies 
severe and non-severe hypoglycemias were considered highly relevant. There was, 
however, a substantial heterogeneity in the deﬁ nition of hypoglycaemias. The surro-
gate parameter HbA1C as primary endpoint was accepted by all agencies investigated 
apart from IQWiG. In its assessments, evidence from randomized as well as from 
observational studies was accepted by NICE. For safety evaluations preclinical studies 
were taken into consideration by EMA and FDA in addition to randomized controlled 
trials. IQWiG on the other hand focused exclusively on randomized controlled trials 
for the assessment of effectiveness as well as safety. CONCLUSIONS: There is a 
substantial variation of criteria applied and evidence considered relevant within the 
assessment process of IQWiG compared to other agencies. This might lead to regional 
variations in the availability of drugs. It is important to be aware of the different 
requirements of agencies, when designing trials and planning market access.
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LEARNING FROM DISEASE MANAGEMENT PROGRAMMES: HOW 
MEDICAL TREATMENTS AND QUALITY OF DIABETIC CARE (TYPE II) 
IN GERMANY ARE DIRECTLY AND INDIRECTLY IMPROVED BY DMPS
Frenzel A1, Reuter A2
1IMS Health GmbH & Co. OHG, Frankfurt, Germany; 2Freie Universität Berlin, Berlin, 
Germany
OBJECTIVES: Disease Management Programmes (DMP) aim at improving care 
quality by implementing standards for medical practices. In the case of Diabetes Mel-
litus Type II (DM II), care improvements can be assessed by the duration between the 
ﬁ rst diagnosis and the occurrence of the ﬁ rst related complication. The aim of this 
longitudinal study is to investigate the direct inﬂ uence of the DMP-based treatments 
on patient outcomes, measured as the postponement of diabetes related complications 
in a large population of DM II patients. The study also investigates how DMP inscrip-
tions of some patients of a medical practice indirectly inﬂ uence patient outcomes of 
DM II patients, who are not inscribed in a DMP, but are treated in the same practise. 
We argue that this indirect effect is due to physicians’ learning from the DMP-based 
treatments in their clinics. METHODS: Using consultation data from IMS Health 
from a period of 25 years (1984–2009) a survival analysis is applied. The data set 
includes 161,747 DM II patients from >1100 practices. Applying a Kaplan–Meier–
Method we test for direct effects of DMPs on patient outcomes. By pooling patients 
by the registration year of the practice-leading physician and by focussing on their 
quarterly consultation rate, we test for indirect effects of DMPs on patient outcomes. 
RESULTS: The mean survival time (duration between ﬁ rst diagnosis and ﬁ rst compli-
cation) of the medical treatment of diabetics in a DMP is 14,82 years, differing sig-
niﬁ cantly from the 15,76 years without a DMP. These tests are controlled for 
following patient variables: sex, age, HbA1C, BMI and the insurance status. Learnings 
from DMPs, indirectly affecting DM care, signiﬁ cantly postpone complications for 
younger physicians and practices with fewer diabetics. CONCLUSIONS: Contributing 
to assessments of DMPs, the study discusses policy implications, as it is shown that 
care quality is improved by physicians learning from DMPs.
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PREDICTORS OF ROUTINE MONITORING OF DIABETES CARE AMONG 
THE US NON-INSTITUTIONALIZED POPULATION: A RETROSPECTIVE 
ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS) IN 
2007
Zhao Y, Fonseca V, Campbell C, Shi L
Tulane University, New Orleans, LA, USA
OBJECTIVES: To examine the rate and predictors of diabetes monitoring in the US. 
METHODS: This cross-sectional retrospective study was conducted on a representa-
tive, non-institutionalized sample of the US population, using the self-reported infor-
mation from the 2007 Household Component (HC) of the MEPS. According to the 
American Diabetes Association (ADA) 2007 practice guidelines, proper provider 
monitoring is deﬁ ned as at least two A1c tests, one eye and one foot examination 
annually. Health status was measured by SF-12®Version2. a logistic regression model 
was used to examine the predictors of proper monitoring. Differences in health status 
and medical expenditures between patients with and without proper monitoring were 
examined using t-tests. Estimates were weighted to the total population (WTP). 
RESULTS: Among 1,747 (WTP: 19,320,394) patients with diabetes, 80.64% had at 
least two A1c tests; 63.29% had an eye examination; and 67.51% had a foot examina-
tion. Thus, 63.36% patients (WTP: 14,065,289) received proper diabetes monitoring. 
Older patients (OR:1.021, 95% conﬁ dence interval [CI]: 1.012–1.030), non-Hispanic 
Caucasians compared with African American patients (OR: 1.236, 95% CI: 0.933–
1.636), patients with a higher education level (OR:1.211, 95% CI: 1.056–1.390), 
insurance coverage (OR:2.216, 95% CI: 1.408–3.486), use of oral anti-diabetic drugs 
(OR:2.935, 95% CI: 2.131–4.042) and insulin (OR:3.453, 95% CI: 2.477–4.814) 
were more likely to undergo the proper monitoring. Well monitored patients had a 
higher Mental Component Summary score (50.09 ± 0.37 vs. 48.51 ± 0.45, P < 0.05), 
but a lower Physical Component Summary score (39.95 ± 0.34 vs. 42.28 ± 0.47, P < 
